The Abbott Alinity I TBI test is a laboratory-based test that measures ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein, two biomarkers in the blood that have been linked to brain injury when present in high concentrations. The test has a sensitivity of 96.7% and a negative predictive value of 99.4%.
The availability of a blood test provides clinicians with an objective method to quickly evaluate patients with mTBIs while eliminating the need for a head CT scan, potentially reducing health care costs and minimizing emergency department wait times.